Paradromius Wins FDA Approval for High-Bandwidth BCI Trial

0:00This is the Let Freedom Podcast News Edition, November 20, 2025. We have some important developments in the news, so we're going to kick it over to Jeremy, and he's going to break that down for us. Here's the news. Brain Computer Interface, BCI, startup Paradromics has just taken a huge leap. The FDA has approved its first human trial of an implant meant to help people with severe motor disabilities regain their ability to communicate. The device, called Connexus, is a small, high-resolution implant, a metal disc with over 400 ultra-thin microwire electrodes that sit directly in the brain's motor cortex, recording signals from individual neurons.

0:40Those signals will be translated into text and synthetic speech, letting participants speak through a computer by thinking about talking. Paradromics isn't just aiming for basic control. Their vision is high-bandwidth communication, fast, fluent, meaningful. In animal tests, they saw transfer rates around 200 bits per second, a number far higher than many competing BCIs. That kind of data flow could let users communicate much faster than existing assistive devices. The first stage of the trial will include just two participants, whose safety and the system's long-term stability will be closely monitored.

1:17The goal is to prove that the device can be safely implanted, remain functional over time, and accurately decode neural signals into language. If everything goes well, the company plans to ask the FDA to expand the study to more patients. Paradramix plans to translate neural intent into speech by asking users to attempt to speak. Even if their vocal muscles can't move, the brain signal associated with trying to talk can be read by the device, converted into text, and played back in the person's own voice, using AI to recreate a voice clone if prior recordings of their speech exist. This trial represents more than a medical milestone.

1:57It's part of a broader showdown in neurotechnology. Paradromics is competing with big names like Neuralink and Synchron, but its strategy is different. Instead of threading ultra-flexible wires or using surface electrodes, it's going for maximum precision, recording densely from individual neurons to maximize speed and fidelity. If successful, this could redefine what BCIs can do. Right now, most implanted devices offer limited control. A cursor here, a robotic arm there. But Conexus promises to go deeper, restoring speech. For people with ALS, spinal cord injuries, or other conditions that impair their ability to speak, that could be life-changing.

2:41Of course, there are serious risks. Brain surgery is never trivial, and implants carry long-term questions around tissue response, device longevity, and data security. Paradromics will have to show that its high-bandwidth system can operate reliably over months and years, not just days. Surgeons and engineers will need to monitor how the brain reacts, whether electrodes stay stable, and if wireless transmission from a chest implant is safe and consistent. There's also a social dimension. Devices like this raise deep ethical and practical questions. Who should get access? Who pays? What happens if the technology improves faster than regulation can keep up?

3:22Companies working on BCIs are already grappling with how to scale from niche clinical applications to broader, more ambitious uses, and regulatory approval is just the first hurdle. Still, for now, this feels like a breakthrough moment. Paradromics is not just building another chip. It's opening a path toward restoring conversation itself. If their trial succeeds, it won't just be a win for tech. It will be a win for people whose voices have been silenced by injury or disease. Bottom line, Paradromic's FDA-approved trial of Conexus is a major milestone in neurotech, a real shot at restoring speech via direct brain interface.

4:03It's a risky experiment, but if it works, it could change lives. Thank you for listening to the Let Freedom Podcast News Edition 2025, November 20th. We can't wait to see you in our full episode tomorrow, and don't forget to rate us on Apple Podcasts. We'll see you in the next one.